LY3410738 + venetoclax + azacitidine

**LY3410738 + venetoclax + azacitidine** is a combination therapy consisting of three agents used together in clinical trials for the treatment of advanced hematologic malignancies, particularly in patients with isocitrate dehydrogenase (IDH1 or IDH2) mutations. LY3410738 is a first-in-class small molecule, oral, covalent inhibitor targeting mutant IDH1 and IDH2 enzymes, disrupting the production of the oncometabolite 2-hydroxyglutarate and restoring normal cellular differentiation[2][5][9]. Venetoclax is a selective small molecule inhibitor of B-cell lymphoma 2 (BCL-2), promoting apoptosis in cancer cells dependent on BCL-2 for survival. Azacitidine is a nucleoside analog and hypomethylating agent that incorporates into DNA and RNA, resulting in DNA hypomethylation and cytotoxicity to abnormal hematopoietic cells. The combination is under investigation for enhanced efficacy in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and related advanced hematologic malignancies, especially in relapsed/refractory settings after standard therapies[2].